Apr. 22 at 8:21 PM
$INDP Former CEO's farewell message on LinkedIn
"After careful consideration, we made the difficult decision to pursue a transaction last year that represents the most responsible outcome for our shareholders under the circumstances."
...
"The challenge we ultimately faced was not the science. It was scale. Advancing this approach through the trials required for approval would likely demand
$50–100 + million. Given our market capitalization and the reality of raising capital for small biotechs over the last few years, continuing independently just simply wasn’t feasible."
